Our Take
Congress is acting on a specific harm—delayed care to seniors—not abstract AI risk, which makes this real pressure, not performative.
Why it matters
Prior authorization already slows treatment decisions; adding AI automation without guardrails has triggered legislative response. Health systems and payers need to watch whether this pilot actually gets blocked and what rules follow.
Do this week
Healthcare IT: audit your current prior auth workflows and flag any AI components to legal and compliance by end of week so you can prepare for potential mandates.
House committee votes to stop Medicare AI prior auth trial
The House Appropriations Committee has moved to block a pilot program testing AI-assisted prior authorization in Medicare, according to Healthcare Dive. The pilot has drawn criticism from lawmakers and patient advocates for delaying care to seniors.
Prior authorization—the process insurers use to approve treatments before they are delivered—has long been a flashpoint in healthcare. Adding machine learning to speed decisions sounded rational on paper. In practice, the pilot faced accusations of slowing treatment rather than accelerating it.
The committee's action is procedural: a legislative step toward defunding or shutting down the trial. The pilot was already under scrutiny; this vote formalizes pressure from Congress.
Congress is targeting a measurable failure, not hype
Unlike abstract warnings about "AI safety," this complaint is concrete: seniors waited longer for care. The concern is not that AI is dangerous in principle but that this specific system made a specific process worse.
That distinction matters. It means the objection is harder to dismiss as anti-tech theater and harder to circumvent with reassuring press releases. Congressional attention to deployment failures—not just capabilities—sets precedent for other healthcare AI rollouts.
Health systems and insurers betting on AI for operational automation (scheduling, coding, triage) should expect similar scrutiny if delays or denials spike during adoption.
What health systems and insurers should do now
Document baseline performance on prior auth turnaround time before deploying any AI component. If an AI system cannot clear that baseline in a sandbox, do not move it to production. Track denial rates and appeal rates separately; a system that speeds approvals but also speeds inappropriate denials is worse than the status quo.
If you are already running AI in prior auth workflows, commission an independent audit of decision latency and accuracy. Do not rely on vendor metrics. If your data shows delays correlated with AI adoption, surface that to compliance and legal now, before a committee asks.